Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
By K. Matthay, C. P. Reynolds, R. Seeger, H. Shimada, E. Adkins, D. Haas-Kogan, R. Gerbing, W. London, J. Villablanca. Journal of Clinical Oncology, 2009
809 citations recorded by the source corpus.
Subfields: Molecular Biology, Neurology
View Paper: https://www.semanticscholar.org/paper/25cfef60e766d7c9df6a1dd9c86148a653c90cb3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Outcomes for children and adolescents with cancer: challenges for the twenty-first century. (2010, background): “Therapeutic interventions evaluated in phase III trials that may account in part for the improvements in survival for children with high-risk neuroblastoma include highdose chemotherapy with autologous stem-cell transplantation and the use of isotretinoin as maintenance therapy.(47,48)”
- Adaptive Interventions Treatment Modelling and Regimen Optimization Using Sequential Multiple Assignment Randomized Trials (Smart) and Q-Learning (2018, background): “These kinds of design are mainly used for trial assignment in areas of ADHD [45], acute myelogenous leukemia [46, 47], small-cell lung cancer [48], neuroblastoma [49, 50], diffuse large cell lymphoma [51], multiple myeloma [52], and metastatic malignant melanoma [53].”
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma (2010, neutral): “Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
- Cancer stem cells: impact, heterogeneity, and uncertainty. (2012, background): “Conversely, poorly differentiated neuroblastomas are often widely disseminated and are usually fatal despite aggressive treatment (Matthay et al., 2009, 1999; Shimada et al., 1999b).”